Identifying factors to predict benefit from bevacizumab in progressive glioblastoma multiforme (GBM).

被引：0
|
作者：
Gleeson, Jack Patrick
Alhusaini, Abdullah
O'Halloran, Philip
Harrold, Emily
Keegan, Niamh M.
Karadawi, Nabeeha Eltag
Mammadov, Emin
Kamel, Dalia
Egan, Keith
Molloy, Susan
Hennessy, Bryan T.
Breathnach, Oscar S.
Grogan, William
Morris, Patrick G.
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷
关键词：
D O I：
10.1200/JCO.2017.35.15_suppl.e13515
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e13515
引用
收藏
页数：6
相关论文
共 50 条
  • [21] The role of the development of hypertension or proteinuria in predicting outcome with the use of bevacizumab for patients with glioblastoma multiforme (GBM).
    Nangia, C. S.
    Wang, D.
    Scarpace, L.
    Schultz, L.
    Khanshour, A.
    Mikkelsen, T.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [22] BEVACIZUMAB (BEV) ALONE OR IN COMBINATION WITH CHEMOTHERAPY IN RECURRENT GLIOBLASTOMA MULTIFORME (GBM): A REAL WORLD EXPERIENCE
    Chalchal, H. I.
    Zhu, T.
    Woitas, C.
    Ahmed, S.
    Souied, O.
    Iqbal, M.
    Ahmed, O.
    Sami, A.
    Dueck, D.
    Magdi, A.
    NEURO-ONCOLOGY, 2021, 23 : 52 - 52
  • [23] Bevacizumab, temozolomide, and radiation therapy followed by bevacizumab, temozolomide, and oral topotecan for newly-diagnosed glioblastoma multiforme (GBM).
    Vredenburgh, J. J.
    Desjardins, A.
    Reardon, D. A.
    Peters, K.
    Kirkpatrick, J.
    Coan, A. D.
    Bailey, L.
    Janney, D.
    Lu, C.
    Friedman, H. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [24] The addition of bevacizumab to temozolomide and radiation therapy followed by bevacizumab, temozolomide, and oral topotecan for newly diagnosed glioblastoma multiforme (GBM).
    Friedman, Henry S.
    Desjardins, Annick
    Peters, Katherine B.
    Reardon, David A.
    Kirkpatrick, John
    Herndon, James Emmett
    Coan, April D.
    Bailey, Leighann
    Sampson, John Howard
    Friedman, Allan H.
    Vredenburgh, James J.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [25] PHASE II STUDY OF BEVACIZUMAB AND TEMSIROLIMUS IN PATIENTS WITH PROGRESSIVE GLIOBLASTOMA MULTIFORME AFTER PRIOR BEVACIZUMAB TREATMENT
    Gaziel, Tine B.
    Soerensen, Morten
    Hasselbalch, Benedikte
    Poulsen, Hans Skovgaard
    Lassen, Ulrik
    NEURO-ONCOLOGY, 2010, 12 : 40 - 40
  • [26] Prognostic Factors of Local Control and Survival in Patients Irradiated for Glioblastoma Multiforme (GBM)
    Witteler, Jaspar
    Schild, Steven E.
    Rades, Dirk
    ANTICANCER RESEARCH, 2020, 40 (12) : 7025 - 7030
  • [27] Bevacizumab (BV) plus irinotecan (I) in recurrent glioblastoma multiforme (GBM): A single center experience.
    Iruarrizaga, Eluska
    Azkona, Eider
    Aresti, Unai
    Rubio, Itziar
    Arruti, Mikel
    Carrera, Sergio
    Fuente, Natalia
    Marrodan, Ines
    Lopez Escola, Cristina
    Condori, Elizabeth
    Manel Mane, Joan
    Lopez-Vivanco, Guillermo
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [28] BEVACIZUMAB (B) PLUS IRINOTECAN (I) IN PROGRESSIVE TEMOZOLOMIDE (T) REFRACTORY GLIOBLASTOMA MULTIFORME (GBM): A SINGLE CENTER EXPERIENCE USING A LOW DOSE REGIMEN
    Dresemann, G.
    Dresemann, A.
    Hobbold, A.
    NEURO-ONCOLOGY, 2008, 10 (06) : 1062 - 1062
  • [29] Do Microscopic Thrombi in Glioblastoma Multiforme (GBM) Predict the Development of Deep Venus Thrombosis (DVT)?
    Prayson, N. F.
    Sethu, S.
    Angelov, L.
    Prayson, R. A.
    LABORATORY INVESTIGATION, 2009, 89 : 334A - 334A
  • [30] Do Microscopic Thrombi in Glioblastoma Multiforme (GBM) Predict the Development of Deep Venus Thrombosis (DVT)?
    Prayson, N. F.
    Sethu, S.
    Angelov, L.
    Prayson, R. A.
    MODERN PATHOLOGY, 2009, 22 : 334A - 334A
12345